What if cellular reprogramming restores organ function in the elderly?
Clean chain: a first in-human partial-reprogramming success restoring organ function triggers a longevity-biotech funding frenzy — private/large-cap longevity plays (Altos/Retro-adjacent, plus listed proxies) and risk-on biotech sentiment lift. No market analogue yet; closest is the Yamanaka-factor reprogramming hype that has driven private longevity valuations. Multi-year, speculative, replication-dependent — the modest risk-on cascade is the right magnitude; this is a theme, not a near-term macro driver.
Every number ships with its receipt — the odds, the range, the precedents, and a public grade at Reality Check. The statistical machinery that produces it is proprietary.
The butterfly cascade
How this trigger trickles across markets, left → right — the root shock, its first‑order moves, then the ripple effects. Drag any node; tap a market for its real price history.
Resolution timeline — how this probability is moving
Our model's odds (electric blue) over time vs the market's (Polymarket, amber), from the past toward the 3–10 years horizon. Each dot is a real macro event that nudged the probability — green pushed it up, red pushed it down. Tap a dot for the source. Loading the probability audit trail…
What it would mean
If this plays out, it is a risk-on shock. First in-human partial cellular-reprogramming trial restores organ function in elderly patients, triggering a longevity-biotech funding frenzy. The trigger decomposes into signed root‑shocks — Risk appetite ▲ — which propagate through our causal graph to the markets below.